Company Company Logo - UC Davis Graduate School of …
Download
Report
Transcript Company Company Logo - UC Davis Graduate School of …
Benjamin Wang MD
2/19/2015
proving Lives one Bottle at a Time
Non-Profit Founded in 2014
Scalable, Self-sustaining Recycling solution to:
Address Homelessness
Create paid volunteer opportunities
Provide affordable green housing
Hand up for education/training
Purpose of Round 2
Still needs to work in 17 seconds
Lead with your stronger slides
Content: Much more than an investor
pitch deck
Must Make Sense
Simple Wording
Don’t read off your slides
Don’t bad mouth your competition
Pitching and Jokes
Personal elements draw the audience into the story
Metaphor, Similes, Secrets, You
Make the audience feel smart
Give them a glimpse of what is coming up, tell them a story
Surprise them
Give them a something good to chew on
Show them that you can bootstrap it
Everything easy has been done
We did that and here are the results
What else can be done without funding
Judging Criteria
Clarity
(How it will make $)
Viability
(How likely it will make $)
1 pt- Unclear Summary
1 pt- Little shown viability
3 pt- Close but needs work
3 pt- Close but needs work
5 pt- Very Clear
5 pt- Strong Viability
Life and Healthcare Saving Innovations
Benjamin R. Wang MD CMO/Founder
8
Nevap Overview
Medical Device to prevent
US Patent Filed (Oct 2013)
3rd Generation Prototype
Team Assembled
Ventilator Associated Pneumonia (VAP)
US Billion problem
9
Team
Janet
Harold
Sandra
Benjamin
Brenton
Kowalyski
Carrison
Forrer
Wang MD
Hanlon
CEO
Regulatory
Engineering
Quality Assurance Founder/CMO
10
Problematic Gold Standard: SSET tube
50,000 US cases each year
300,000 US at risk/yr
Avr Treatment cost $40K
Source: Center of Disease Control & Prevention
11
Problematic Gold Standard: SSET tube
50,000 US cases each year
300,000 US at risk/yr
Avr Treatment cost $40K
No Medicare reimbursement
Growing Global ICU needs
Source: Center of Disease Control & Prevention
12
Problematic Gold Standard: SSET tube
50,000 US cases each year
300,000 US at risk/yr
Avr Treatment cost $40K
No Medicare reimbursement
Growing Global ICU needs
Era of Multi-antibiotic resistance
“Superbugs”
Source: Center of Disease Control & Prevention
13
Ventilator Associated Pneumonia
Source: Medscape, Pubmed, Youtube.com
Solution: Nevap Suction Line ET tube
Core Competencies
Simple & Effective
Unique
Low Risk
Integratable
Manufacturable
16
Solution: Nevap Suction Line ET tube
Core Competencies
Simple & Effective
Unique
Low Risk
Integratable
Manufacturable
Class II Device, Predicate Devices needed only bench testing to gain
FDA clearance.
17
Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists”
-Lynn White MD Anesthesiologist/CEO Patient Shield Concepts
19
Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists”
-Lynn White MD Anesthesiologist/CEO Patient Shield Concepts
“When will this be available for clinical testing? I’ll write up a proposal”
-Arash Esmailzadegan MD Anesthesiologist
20
Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists”
-Lynn White MD Anesthesiologist/CEO Patient Shield Concepts
“When will this be available for clinical testing? I’ll write up a proposal”
-Arash Esmailzadegan MD Anesthesiologist
“If it can live up to its claims, this could help a lot of people,”
-Jim Fink PhD Respiratory Industry Expert.
21
Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists”
-Lynn White MD Anesthesiologist/CEO Patient Shield Concepts
“When will this be available for clinical testing? I’ll write up a proposal”
-Arash Esmailzadegan MD Anesthesiologist
“If it can live up to its claims, this could help a lot of people,”
-Jim Fink PhD Respiratory Industry Expert.
“This sounds very promising, when will we have more data in patients”
-Mike Rosenthal MD Anesthesiologist/ Professor Emeritus
22
Competitive Devices
23
Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims
No Suction Blockage
Regardless of patient movement
Reinforced Suction Sealing
Safely change tubes
24
Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims
No Suction Blockage
Regardless of patient movement
Reinforced Suction Sealing
Safely change tubes
Better Outcomes/Re-admissions
Save Hospital $$$ Billions
Decrease Legal Liability
25
Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims
No Suction Blockage
Regardless of patient movement
Reinforced Suction Sealing
Safely change tubes
Better Outcomes/Re-admissions
Save Hospital $$$ Billions
Decrease Legal Liability
Lower rates of “Superbugs”
Additional Device Applications
26
Competitive Landscape
Conservatively, estimate VAP reduction rates of 75% & US Hospital Savings of $9B/yr
Covidien
Kimberly
Clark
Teleflex
Market Rank
1
2
3
Device Cost
$40
$43
$40
Tbd
Residual
Secretions
++
++
++
++++
Border
Suctioning
++
++
++
+++++
Suction
Blockage Rate
++-
++-
++-
+++++
Airway
Sealing
++
++
++
+++++
+++
+++
+++
+++++
Mucosal harm
Nevap
-
28
US VAP Market Opportunity
350K Patients X $40/tube X 3.5used = $50M
Nevap US TAM = $150M/yr
Target
Segment
29
US VAP Market Opportunity
350K Patients X $40/tube X 3.5used = $50M
Nevap US TAM = $150M/yr
Target
Segment
Key Decision
Makers
Anesthesiologists/Critical Care
Nursing/Respiratory Therapy
Hospital Administration
30
US VAP Market Opportunity
350K Patients X $40/tube X 3.5used = $50M
Nevap US TAM = $150M/yr
Target
Segment
Key Decision
Makers
Anesthesiologists/Critical Care
Nursing/Respiratory Therapy
Hospital Administration
Saves $Billions/ Better Outcomes
Key Benefits
Readily Integrated
Increase Hospital Revenue
31
Value Proposition
(6 day ICU Stay)
Gold Standard (1 tubes used)
X $40= $40(purchase price)
Hospital Profits
15
$
Hospital Savings
$
X $55= $55(Medicare reimbursement)
0
Net Hospital Profit $15
Competition Profit
Costs ($-5328)
Incidence:
22.2/1000days
$34
X $40,000
Nevap (2 VAP
tubesRisk
used)
Hospital
Profits
$ 30
average cost
X $40= $80(purchase price)
Hospital Savings
$
4128
X $55= $110 (Medicare reimbursement)
Nevap Profit
$ 68
Net Hospital Profit $30
VAP Risk Costs ($-1200)
Incidence: 5/1000days X $40,000 average
Nevap New CPT Coding (2 tubes used)
Hospital Profits
$ 40
cost
X $60= $120(purchase price)
Hospital Savings
4128
X $80= $160(Medicare reimbursement)
Nevap Profit
Net Hospital Profit $40
$
$ 102
Current Competition Profile
Physician Bills One procedure
Hospital Profits
Hospital Savings
Competition Profit
$ 15
$0
$34
Nevap $40 Price Point
Physician Bills One procedure
Hospital Profits
Hospital Savings
Competition Profit
$ 15
$0
$34
Physician Bills Two procedures
Hospital Profits
Hospital Savings
Nevap Profit
$ 30
$ 4128
$ 68
Nevap $60 Price Point
Physician Bills One procedure
Hospital Profits
Hospital Savings
Competition Profit
$ 15
$0
$34
Physician Bills Two procedures
Hospital Profits
Hospital Savings
Nevap Profit
$ 40
$ 4128
$ 102
US TAM is $150M, Global Tam $450M
Strategic Manufacturing Partner
www.bioteq.com.tw
Low Capital Equipment Costs
Rapid & Experienced OEM Expertise
Existing Bioteq Distribution
Rapid high precision scalability
Licensing/Partnership for small market countries
Est. COG: <$2.00 (package, shipped)
37
Market Strategy: Promotion/Sales
1.
Generate Independent Clinical Data through existing
network of Academic physicians (UM, NYU, etc)
Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing
network of Academic physicians (UM, NYU, etc)
2. Target Anesthesia & Critical Care Groups through
Publication, Medical Conferences, and Trade Shows
1.
Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing
network of Academic physicians (UM, NYU, etc)
2. Target Anesthesia & Critical Care Groups through
Publication, Medical Conferences, and Trade Shows
3. Target & Garner thought leader Endorsements
1.
Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing
network of Academic physicians (UM, NYU, etc)
2. Target Anesthesia & Critical Care Groups through
Publication, Medical Conferences, and Trade Shows
3. Target & Garner thought leader Endorsements
1.
4. Apply for Unique CMS coding
Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing
network of Academic physicians (UM, NYU, etc)
2. Target Anesthesia & Critical Care Groups through
Publication, Medical Conferences, and Trade Shows
3. Target & Garner thought leader Endorsements
1.
4. Apply for Unique CMS coding
5. Target large hospital chains & distributorship for private
labeling/licensing
US Business Strategy
(sell on 10 unit basis)
Beachhead sales
Academic Researchers
Promotional target price $10 / free
Est. COG: $2.00 (package, shipped)
Gross Margins Est: 85+%
US Business Strategy
(sell on 10 unit basis)
Beachhead sales
Academic Researchers
Promotional target price $10 / free
Anesthesia Groups
Promotional target price $40
Est. COG: $2.00 (package, shipped)
Gross Margins Est: 85+%
US Business Strategy
(sell on 10 unit basis)
Beachhead sales
Academic Researchers
Promotional target price $10 / free
Anesthesia Groups
Promotional target price $40
Distributors
Target price $60
Est. COG: $2.00 (package, shipped)
Gross Margins Est: 85+%
Milestones
46
Financial Projections
Q2
Q3
Q4
Yr1
Yr2
Yr3
Yr4
Yr5
Sales
0
0.02
0.15
0.17
3.0
7.0
13.0
27.0
Gross
Margins
0
0.015
0.14
0.155
2.65
6.3
11.7
24.3
Marketing
Sales
0
0.01
0.02
0.03
0.3
0.6
1.0
2.0
QA/Mfg
0.01
0.02
0.02
0.05
0.1
0.15
0.15
0.15
Admin
0.01
0.02
0.03
0.06
0.4
0.5
0.7
0.8
Total Exp
0.02
0.05
0.08
0.15
0.8
1.25
1.85
2.95
EBITDA
-0.02
-0.035
0.06
0.02
1.85
5.05
9.85
21.25
Amounts in
Millions
*Est. GM = 85+%
Break Even
----
---
Profitability
------
-
Ask
$1M/20% equity
($350,000),
PCT Filing
Pilot Run
IDE Study/Process Validation/ Quality Systems,
Design History File,
$ 100K
$ 250K
Prototype
US Patent
($170,000)
Biocomp Testing
Stability Testing
CE Mark
CMS Application, Stage II SBIR Grant,
$ 100K
$ 50K
$ 20K
510K
$ 40K
Legal/Accounting
Salaries
Business Dev
$ 40K
$ 250K
$ 150K
Team Assembled
Consultants Identified
($40,000)
Completed Milestones
Manufacturing Partner
Founders Funding to date: $60,000
Raised to date: $350,000
48
Summary
Nevap Suction Line Endotracheal Tube
-Help hundreds of thousands US patients/yr
-Saves US hospitals $Billions/yr
1. Functional Prototype, Patent Pending
2.Enormous Societal & Financial Returns
3.Key Team of Professionals
4.Physicians embrace design
5.Strong Incentives
Benjamin R. Wang MD
(408) 398-5159
[email protected]
49
Questions?